Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## **Revision of Precautions** Tacrolimus hydrate (ointment)

July 10, 2018

## Non-proprietary name

Tacrolimus hydrate (ointment)

## Safety measure

Precautions should be revised in the package insert.

"Pregnant women or women who may be pregnant" should be deleted from the Contraindications section.

Language concerning pregnant women or women who may be pregnant in the Use during Pregnancy, Delivery or Breastfeeding section should be revised as follows (revised language is underlined):

Pregnant women etc.:

Pregnant women or women who may be pregnant <u>should be administered this drug only if</u> <u>the potential therapeutic benefits are considered to outweigh the potential risks.</u> [Teratogenic effects and fetal toxicity have been reported as observed in animal studies (rabbits, orally administered.) <u>Placental transfer in humans (orally administered) has been</u> <u>reported</u>]

(References) Saegusa,T.,et al. :The Clinical Report 1992;26(3):969 Zheng,S.,et al. :Br.J.Clin.Pharmacol. 2013;76(6):988

> Pharmaceuticals and Medical Devices Agency Office of Safety I 3·3·2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>